Skip to main content
AmigoFish

BioVenture VoiCes with Chris Garabedian

BiotechTVAudio

Format:
Podcast
New episodes:
Every two weeks
Typical length:
about 1 hour 10 minutes
Latest episode:
Not rated yet
CosmosOpen at the sourceReport a problemIs this your show? Get a badge

About this show

Hosted by Chris Garabedian, meet the leading Voices in the BioVenture community and hear their insights and perspectives on the challenges and successes with VC investing.

Covers: biotech, venture capital, life sciences investing, healthcare investing, biopharma industry, startup funding, medical devices, precision oncology

Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.

Recently on this show

Summary of recent episodes, drawn from the publisher's feed.

This podcast features conversations with leading venture investors in biotech about the challenges and successes of backing companies. Recent episodes cover corporate venture investing with Sanofi Ventures' Jason Hafler and early biotech history with Third Rock Ventures' Bob Tepper.

Report a problem with this summary

Cosmos

Similar in subject

See the full Cosmos

Similar shows

See all Science shows

Explore more

Episodes

  • Episode 32: ARCH Venture Partners' Bob Nelsen

    · 1 hr 15 min

    While describing his early life in Washington and formative years at the University of Chicago that led to the founding of ARCH, he shares his thoughts on leadership, risk taking, changes he thinks are need to keep the United States competitive in life sciences, and his belief in AI's promise to transform our industry.

    Not rated yet
  • Episode 31: Polaris Partners' Amy Schulman

    · 1 hr 2 min

    She describes her career beginnings as a lawyer, which led to general counsel and business unit head roles at Pfizer, and then joining the VC world at Polaris Partners (at Bob Langer's urging). She discusses the firm's investment philosophy, the nuances behind how companies choose lead assets, and the cycles biotech has been through over the last ten years. Plus, other roles she currently serves, including being the chair of Alnylam.

    Not rated yet
  • Episode 30: F-Prime Capital Senior Managing Partner Stephen Knight

    · 1 hr 0 min

    He describes his early life and career experiences at Bell Labs, consulting work, and EPIX Pharmaceuticals before landing in his true interest, venture capital. Dr. Knight describes the foresight of Fidelity to focus on life sciences in its early days, and F-Prime's investing philosophy today.

    Not rated yet
  • Episode 29: Averin Managing Partner David Berry

    · 1 hr 19 min

    He describes his early life and education, 18 years of company building at Flagship Pioneering, founding Averin (previously called Bedford Bridge) with his brother, and investing at the intersection of healthcare and technology.

    Not rated yet
  • Episode 28: Hatteras Venture Partners' Clay Thorp

    · 1 hr 0 min

    Clay Thorp describes his early education and becoming a business partner to his brother on a genomics startup. He describes the genesis of Hatteras, the history and strengths of the life sciences ecosystem in the North Carolina area, and his philosophy of backing founders.

    Not rated yet
  • Episode 27: Avalon Bioventures' Jay Lichter

    · 1 hr 3 min

    Jay Lichter describes his roots growing up in Chicago, Yale, and an early career role at DuPont Merck before getting a call from Kevin Kinsella to try the world of venture at Avalon. Since that pivotal move, he describes numerous companies he either operated or funded, leading to his work today at Avalon Bioventures.

    Not rated yet
  • Episode 26: venBio's Corey Goodman

    · 1 hr 21 min

    Corey Goodman shares learnings for his career in biotech, including working in academia, biotech, pharma, and as a venture capital investor. He describes the unique learnings from all of them and why he is thankful that he has experienced these different components of life sciences.

    Not rated yet
  • Episode 25: Atlas Venture's Bruce Booth

    · 1 hr 18 min

    Bruce Booth discusses his education and early career, the structure of Atlas and the types of investments it makes, investing in assets vs platforms, and more.

    Not rated yet
  • Episode 24: Samsara Biocapital's Srini Akkaraju

    · 1 hr 12 min

    The Founder & Managing Partner of Samsara Biocapital, Dr. Akkaraju describes his early move from Standford to industry and various investment firms he worked for before founding Samsara in 2016. He discusses how the firm invests in all stages of life sciences companies and why he believes patience is a key virtue.

    Not rated yet
  • Episode 23: a16z's Vineeta Agarwala

    · 1 hr 20 min

    Still a practicing physician today, Vineeta Agarwala describes her educational background and early career, including experiences at the Broad Institute, Flatiron Health, and GV (Google Ventures). She talks about a16z's investment philosophy of "providing more than just a check," and a recent $500M fund partnered with Lilly.

    Not rated yet
  • Episode 22: Adjuvant Capital's Glenn Rockman

    · 1 hr 12 min

    Glenn Rockman describes the introduction to impact investing he gained from working for J.P. Morgan and along with the Gates Foundation on the Global Health Investment Fund, and how the idea of investing for public good ultimately sparked Adjuvant Capital in 2019. Armed with a $300M+ fund that was raised from numerous foundations and for-profit funds in 2021, Adjuvant has been investing in public health technologies, post proof of concept, to help accelerate their development and ultimately make them more accessible to those around the world who need them.

    Not rated yet
  • Episode 21: Scion Life Sciences' Aaron Kantoff

    · 1 hr 10 min

    Aaron Kantoff describes the road on the public markets side that eventually led him to venture, and recalls successful investments he helped lead at firms like Apple Tree Partners and Medicxi, such as Stoke Therapeutics, Akero Therapeutics, Centessa Pharmaceuticals, and RayzeBio. He discusses founding Scion with his partner, Samuel Hall, and describes raising their first fund and how the firm has a longer outlook than is traditionally thought of in venture.

    Not rated yet
  • Episode 20: Breakout Ventures' Lindy Fishburne

    · 1 hr 7 min

    Lindy Fishburne describes her educational background and career, and transitioning from the philanthropic Breakout Labs within the Thiel Foundation to Breakout Ventures, a traditional venture firm that has a diverse set of limited partners. Plus, how she is navigating these challenging times in healthcare and biotech.

    Not rated yet
  • Episode 19: Longwood Fund's Christoph Westphal

    · 1 hr 3 min

    Dr. Westphal describes his upbringing and early career at McKinsey and Polaris, founding or co-founding companies like Momenta, Alnylam, Sirtris, Acceleron, and VeraStem, and creating the Longwood Fund. He shares his thoughts on venture investing, the current environment in biotech, focusing on creating new medicines, and his love of the Boston ecosystem.

    Not rated yet
  • Episode 18: Playground Global's Jory Bell

    · 1 hr 16 min

    Jory Bell shares the details of his expansive educational background and early career, which included being a product designer at Apple during the return of Steve Jobs. He describes Playground's engineering and tech angle to investing in life sciences, and weighs in on sizable seed and pre-seed investments the industry has seen lately that get startups to a proof of concept.

    Not rated yet
  • Episode 17: Norwest Venture Partners' Tiba Aynechi

    · 55 min

    Tiba Aynechi describes her career path, which has been spent entirely in the Bay Area since she earned her PhD from UCSF in the early 2000's. She describes the value of BD experience she earned while working on licensing deals early in her career, her more than a decade at Novo Ventures, and what appealed to her to join Norwest. Plus, her thoughts on a board of directors' relationship with management teams.

    Not rated yet
  • Episode 16: RA Capital's Josh Resnick

    · 1 hr 12 min

    Josh Resnick describes his career path, which includes working on the venture side of both private funds and pharma (Merck). He explains the different investment strategies of RA Capital, and talks about how the firm's Raven company building incubator fits in. Plus, his thoughts on venture investing in the current environment.

    Not rated yet
  • Episode 15: Mission BioCapital's Steve Tregay

    · 1 hr 1 min

    Steve Tregay describes his career path, including how early roles at Array BioPharma and Novartis led him to found Forma Therapeutics. He describes the founding and growth of LabCentral, for which he is still the chairman today, and how getting a look at entrepreneurs at such an early stage naturally led to the investment work that he and his partners do at Mission BioCapital.

    Not rated yet
  • Episode 14: Aditum Bio's Joe Jimenez

    · 1 hr 13 min

    Joe Jimenez describes the career path in consumer products that led him to pharma, his time running Novartis, and the idea to co-found Aditum Bio with his partner Mark Fishman. He explains Aditum's investment philosophy, and why they like focusing on translational medicine opportunities that are just heading into the clinic. Plus, his thoughts on making R&D more efficient.

    Not rated yet
  • Episode 13: Civilization Ventures' Shahram Seyedin-Noor

    · 1 hr 12 min

    Shahram describes his upbringing as a refugee from Iran, his early career in law and banking, and how his initial experience in the tech industry has benefitted his eye towards life sciences. He recalls founding Civilization Ventures with an initial $1M fund, and talks about what it has quickly grown into today, Plus, his take on AI and the current state of tech bio.

    Not rated yet

More from BiotechTV

See all shows by BiotechTV